Inventor · disambiguated record
Chakravarthy Nachu Narasimhan
Also filed as: NARASIMHAN CHAKRAVARTHY · NARASIMHAN CHAKRAVARTHY NACHU
6 granted patents·10 pending applications·315 citations·filing 1998–2024
86Inventor score
Files withMERCK SHARP & DOHME LLC5MERCK SHARP & DOHME4LILLY CO ELI3FORREST JR WILLIAM P1MASSACHUSETTS INST TECHNOLOGY1
Top patents by PatentIndex Score
16 records- 0196US6555521B2Glucagon-like peptide-1 crystalsLILLY CO ELI·Filed 2001·Granted Apr 29, 2003·120 cites·6 claims
- 0293US6380357B2Glucagon-like peptide-1 crystalsLILLY CO ELI·Filed 1998·Granted Apr 30, 2002·113 cites·13 claims
- 0388US11633476B2Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereofMERCK SHARP & DOHME LLC·Filed 2018·Granted Apr 25, 2023·6 cites·21 claims
- 0486US9220776B2Stable formulations of antibodies to human programmed death receptor PD-1 and related treatmentsSHARMA MANOJ K·Filed 2012·Granted Dec 29, 2015·67 cites·13 claims
- 0583US9803010B2Crystalline anti-human IL-23p19 antibodiesMERCK SHARP & DOHME·Filed 2013·Granted Oct 31, 2017·5 cites·8 claims
- 0681USRE41133EGlucagon-like peptide-1 crystalsLILLY CO ELI·Filed 2005·Granted Feb 16, 2010·4 cites·14 claims
- 0779US2023263887A1Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereofMERCK SHARP & DOHME LLC·Filed 2023·Application pending·0 cites
- 0879US2023321234A1Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereofMERCK SHARP & DOHME LLC·Filed 2023·Application pending·0 cites
- 0970US2025074985A1Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereofMERCK SHARP & DOHME LLC·Filed 2024·Application pending·0 cites
- 1069US2024182573A1Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereofMERCK SHARP & DOHME LLC·Filed 2024·Application pending·0 cites
- 1156US2025092138A1Compositions including solid forms of polypeptides and related methodsMASSACHUSETTS INST TECHNOLOGY·Filed 2021·Application pending·0 cites
- 1252US2020262922A1Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereofMERCK SHARP & DOHME·Filed 2018·Application pending·0 cites
- 1348US2021380694A1Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereofFORREST JR WILLIAM P·Filed 2019·Application pending·0 cites
- 1446US2021236640A1Rapid method to predict stabilities of pharmaceutical compositions containing protein therapeutics and non-reducing sugarsMERCK SHARP & DOHME·Filed 2019·Application pending·0 cites
- 1545US2020354453A1Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereofMERCK SHARP & DOHME·Filed 2018·Application pending·0 cites
- 1632US2019010224A1Formulations of engineered anti-il-10 antibodiesNarasimhan NARASIMHAN·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →